In their previous studies, they similarly found that IL-20 promoted tumor growth in HCC, breast and oral cancer, and anti-IL-20 mAb treatment in a mouse model of cancer effectively mitigated the release of inflammatory mediators, inhibited tumor growth, and improved survival rates. This evidence concerns the gene IL20 and neoplasm.